drugset / Trial / NCT05667740
Safety, Tolerability and Immunogenicity of an Inactivated Whole-cell Pneumococcal Vaccine Gamma-PN3.
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a randomised placebo-controlled first-in-man dose-ranging study to determine safety and markers of efficacy.
Timeline
- Start
- 2023-01-16
- Primary completion
- 2023-10-08
- Completion
- 2023-10-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gamma-PN3 | Vaccine | 50 ug | — |
| Subject | Gamma-PN3 | Vaccine | 250 ug | — |
| Subject | Gamma-PN3 | Vaccine | 1000 ug | — |
| Comparator | Pneumovax 23 | Vaccine | — | — |
| Comparator | Prevenar 13 | Vaccine | — | — |